Financials
Financial year 2025
Worth noting
- A loss two years in a row.
Gross margin
€ 883,559
▲ 27% vs 2024
Profit
Caution€ -201,723
▼ 159% vs 2024
Debts
Low€ 896,755
▲ 7% vs 2024
ImmuneSpec from Niel, company number BE0797707610, closed financial year 2025 with a result of € -201,723 after tax. For that financial year ImmuneSpec recorded a gross margin of € 883,559 and equity of € 2.6 million. Compared with financial year 2024, the result moved from € -77,917 to € -201,723. The company made a loss. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 8, 2026.
What happened at ImmuneSpec?
What happened at ImmuneSpec in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 201,723. Source: NBB ↗
- Clean Vision Invest BV became a director. NBB
- Thibault Jonckheere became a director. NBB
- Heran Partners BV became a director. NBB
- New establishment in Niel. KBO
- Start of the company according to the CBE. KBO
- Elise Pepermans became a director. NBB
In short
From € 397,068 loss in 2023 to € 201,723 loss in 2025.
On average € 155,000 of value added per employee in 2025.
A new publication or filing at ImmuneSpec? We notify you, reason included.
Follow ImmuneSpecNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Behind ImmuneSpec are Elise Pepermans, Heran Partners BV, Thibault Jonckheere and Clean Vision Invest BV. The same people are also behind Lynxcare Clinical Informatics, FOx Biosystems, ASPECT ANALYTICS, Heran HealthTech Fund I and nuclivision.
Directors
According to the 2025 annual accounts
Elise Pepermans
Director
since 2023
Director · represented by Geoffrey D'hondt
Also active at: Lynxcare Clinical Informatics, FOx Biosystems, ASPECT ANALYTICS +5 more
since 2023
Thibault Jonckheere
Director
since 2023
Director · represented by Bart Swaelens
since 2023
Establishments
Establishment units
Physical locations of this company
Galileilaan 18 box 6
2845 Niel
Galileilaan 18
2845 Niel
Active since 27 January 2023
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 11 companies are registered at this address.
NIEUWE MEDIA GROEP
€ 2.2 million revenue · 2025
UNITED CONSULTING
€ 82.2 million revenue · 2025
XPAND
€ 948,746 revenue · 2025
iFLUX
€ 449,843 gross margin · 2025
Vereniging van Mede-eigenaars van het gebouw Residentie Archimedesgebouw Galileilaan 18 te Niel
+6 more
Details
- Company number
- 0797.707.610
- VAT number
- BE 0797.707.610
- Registered office
- Galileilaan 18 bus 6, 2845 Niel
- Names & denominations
- ImmuneSpec
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 27 January 2023
- Peppol
- Active · Active since 2 Jul 2025
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied